Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: A retrospective review of 15 cases and analysis of risk factors

Modern Rheumatology

Volumn 22, Issue 6, 2012, Pages 849-858

  Tanaka, Michi ^a   Sakai, Ryoko ^a   Koike, Ryuji ^a,b   Komano, Yukiko ^a   Nanki, Toshihiro ^a   Sakai, Fumikazu ^c   Sugiyama, Haruhito ^d   Matsushima, Hidekazu ^e   Kojima, Toshihisa ^f   Ohta, Shuji ^g   Ishibe, Yoji ^h   Sawabe, Takuya ⁱ   Ota, Yasuhiro ^j   Ohishi, Kazuhisa ^k   Miyazato, Hajime ^l   Nonomura, Yoshinori ^a   Saito, Kazuyoshi ^m   Tanaka, Yoshiya ^m   Nagasawa, Hayato ⁿ   Takeuchi, Tsutomu ^o   Nakajima, Ayako ^p   Ohtsubo, Hideo ^q   Onishi, Makoto ^r   Goto, Yoshinori ^s   Dobashi, Hiroaki ^t   Miyasaka, Nobuyuki ^a   Harigai, Masayoshi ^a   more..

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e SAITAMA RED CROSS HOSPITAL   (Japan)

^f NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g HITACHI LTD   (Japan)

^h Saijo Central Hospital   (Japan)

ⁱ ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^j Yasuhiro Clinic   (Japan)

^k HAMAMATSU MEDICAL CENTER   (Japan)

^l Shunan Memorial Hospital   (Japan)

^m UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

ⁿ SAITAMA MEDICAL UNIVERSITY   (Japan)

^o KEIO UNIVERSITY   (Japan)

^p TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^q SUWA RED CROSS HOSPITAL   (Japan)

^r Dohogo Spa Hospital   (Japan)

^s Goto Medical Clinic   (Japan)

^t KAGAWA UNIVERSITY   (Japan)

more..

Author keywords

Anti TNF therapy; Etanercept; Opportunistic infection; Pneumocystis jirovecii pneumonia; Rheumatoid arthritis

Indexed keywords

COTRIFAMOLE; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; PENTAMIDINE ISETHIONATE;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LABORATORY TEST; LUNG DISEASE; MALE; MORTALITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIFUNGAL AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES;

EID: 84870319550     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0615-z     Document Type: Review

References (40)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397-440.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-Tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194): 1932-9.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381-90.
4. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007; 370(9602):1861-74.
5. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-Tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896-904.
6. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-Tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368-76.
7. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol. 2011; 38(7):1258-64.
8. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-Analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-85.
9. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol. 2009;36(5):898-906.
10. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189-94.
11. Koike T, Harigai M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2011 (Epub ahead of print).
12. Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, Battegay M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999;340(17):1301-6.
13. Limper AH, Offord KP, Smith TF, Martin WJ 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis. 1989;140(5):1204-9.
14. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-Alpha antagonists. Drug Saf. 2004;27(5):307-24.
15. Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2010; 6(11):644-52.
16. Krajicek BJ, Thomas CF Jr, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med. 2009;30(2):265-78, vi.
17. Khot PD, Fredricks DN. PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther. 2009;7(10):1201-21.
18. Marty FM, Koo S, Bryar J, Baden LR. (1 × 3)Beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jirovecii pneumonia. Ann Intern Med. 2007;147(1):70-2.
19. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007;131(4):1173-80.
20. Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med. 2011;50(4):305-13.
21. Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med. 2008;47(10):915-23.
22. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum. 2009; 61(3):305-12.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
24. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357(18): 1874-6.
25. NakajimaH,HarigaiM,HaraM,HakodaM,TokudaH, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27(5):1164-70.
26. Nakamura H, Tateyama M, Tasato D, Haranaga S, Yara S, Higa F, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med. 2009;48(4): 195-202.
27. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350(24):2487-98.
28. Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care. 2008;12(1):R28.
29. Ewig S, Bauer T, Schneider C, Pickenhain A, Pizzulli L, Loos U, et al. Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients. Eur Respir J. 1995;8(9):1548-53.
30. Thomas CF Jr, Limper AH. Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Semin Respir Infect. 1998;13(4): 289-95.
31. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34(8):1098-107.
32. Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol. 2006;16(5):282-8.
33. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113(5):1215-24.
34. Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillevin L, Magadur G, De Bandt M, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol. 1994;21(2):246-51.
35. Delclaux C, Zahar JR, Amraoui G, Leleu G, Lebargy F, Brochard L, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29(3):670-2.
36. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 1999;42(4):780-9.
37. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis. 2009;69(2):380-6.
38. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-Tumor necrosis factor therapy. Arthritis Rheum. 2006; 54(2):628-34.
39. Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons -2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2002;137(5 Pt 2):435-78.
40. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294-300.